Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Comment: (RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients

Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

(RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients

High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer

N-803-BCG combination shows promising results in BCG-unresponsive NMIBC

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma

Everolimus after surgery can improve outcomes in those with high-risk kidney cancer